These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9449042)

  • 41. The insulin-like growth factor-I receptor as an oncogene.
    Werner H; Bruchim I
    Arch Physiol Biochem; 2009 May; 115(2):58-71. PubMed ID: 19485702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor.
    Surmacz E; Sell C; Swantek J; Kato H; Roberts CT; LeRoith D; Baserga R
    Exp Cell Res; 1995 May; 218(1):370-80. PubMed ID: 7737373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.
    Grimberg A; Cohen P
    J Cell Physiol; 2000 Apr; 183(1):1-9. PubMed ID: 10699960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.
    Tolmachev V; Malmberg J; Hofström C; Abrahmsén L; Bergman T; Sjöberg A; Sandström M; Gräslund T; Orlova A
    J Nucl Med; 2012 Jan; 53(1):90-7. PubMed ID: 22173843
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlling IGF-receptor function: a possible strategy for tumor therapy.
    Baserga R
    Trends Biotechnol; 1996 May; 14(5):150-2. PubMed ID: 8645448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1.
    Pietrzkowski Z; Mulholland G; Gomella L; Jameson BA; Wernicke D; Baserga R
    Cancer Res; 1993 Mar; 53(5):1102-6. PubMed ID: 8439954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IGF-IR: potential role in antitumor agents.
    Guerreiro AS; Boller D; Doepfner KT; Arcaro A
    Drug News Perspect; 2006 Jun; 19(5):261-72. PubMed ID: 16941048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins.
    Dews M; Nishimoto I; Baserga R
    Recept Signal Transduct; 1997; 7(4):231-40. PubMed ID: 9633824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin-like growth factors I and II are autocrine factors in stimulating proteoglycan synthesis, a marker of differentiated chondrocytes, acting through their respective receptors on a clonal human chondrosarcoma-derived chondrocyte cell line, HCS-2/8.
    Takigawa M; Okawa T; Pan H; Aoki C; Takahashi K; Zue J; Suzuki F; Kinoshita A
    Endocrinology; 1997 Oct; 138(10):4390-400. PubMed ID: 9322955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
    Byron SA; Horwitz KB; Richer JK; Lange CA; Zhang X; Yee D
    Br J Cancer; 2006 Nov; 95(9):1220-8. PubMed ID: 17043687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
    Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
    Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.
    Shahid A; Santos SG; Lin C; Huang Y
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
    Andrews CE; Zilberberg J; Perez-Olle R; Exley MA; Andrews DW
    J Neurooncol; 2023 Dec; 165(3):389-398. PubMed ID: 38017340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.
    Song K; Shankar E; Yang J; Bane KL; Wahdan-Alaswad R; Danielpour D
    PLoS One; 2013; 8(5):e61896. PubMed ID: 23658701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer.
    Philippou A; Armakolas A; Koutsilieris M
    Front Endocrinol (Lausanne); 2013; 4():31. PubMed ID: 23519101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.
    Durfort T; Tkach M; Meschaninova MI; Rivas MA; Elizalde PV; Venyaminova AG; Schillaci R; François JC
    PLoS One; 2012; 7(1):e29213. PubMed ID: 22235273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the p53 Pathway in Ewing Sarcoma.
    Neilsen PM; Pishas KI; Callen DF; Thomas DM
    Sarcoma; 2011; 2011():746939. PubMed ID: 21197471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.